Our findings revealed that omega‐3 fatty acids supplementation as an augmentation therapy to improve BDNF and hs‐CRP serum levels, physical activity, and chronic fatigue in MS was not significantly different from placebo in this randomized, double‐blind, placebo‐controlled trial. The gene discussed is BDNF; the disease is myeloid sarcoma.